Table 3 RFS from randomization for TP53 and BRCA.

From: Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy

Gene 1

Gene 2

Vigil median RFS (months)

Placebo median RFS (months)

Difference (months)

N

P-value

HR

Vigil

Placebo

BRCAm

TP53m

11.71

14.75

−3.04

4

14

0.27

1.50

BRCAwt

TP53m

19.35

7.85

11.50

29

18

0.013

0.44

BRCAm

TP53wt

10.48

31.90

−21.42

3

3

0.39

1.40

BRCAwt

TP53wt

10.48

8.38

2.10

11

9

0.47

1.05

Back to article page